Drugs / Gecacitinib
Gecacitinib
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07565597 | May 2026 → Feb 2027 expected | — | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Active not recruiting | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT07476872 | Mar 2026 → Nov 2027 expected | chronic graft versus host disease | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07285889 | Dec 2025 → Dec 2027 expected | acute graft versus host disease | First Affiliated Hospital of Zhejiang University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07080216 | Sep 2025 → Aug 2027 expected | cervical cancer | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07142837 | Sep 2025 → Oct 2027 expected | neoplasm | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07012304 | Jun 2025 → Feb 2027 expected | chronic graft versus host disease | Yujun DONG | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06903377 | May 2025 → Apr 2027 expected | non-small cell lung carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06883526 | May 2025 → Apr 2027 expected | lymphoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07471503 | Mar 2026 → Apr 2029 expected | myelofibrosis | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07197112 | Oct 2025 → Feb 2027 expected | acute graft versus host disease | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07185633 | Oct 2025 → Oct 2026 expected | acute graft versus host disease | Bin Gu | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07157306 | Sep 2025 → Jan 2027 expected | hepatocellular carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT07454226 | May 2026 → Mar 2028 expected | acute lymphoblastic leukemia, phosphohydroxylysinuria | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| — | NCT07445893 | Apr → Dec 2026 expected | acquired polycythemia vera | Duan Minghui | Recruiting | No outcome recorded |
| — | NCT07440654 | Mar 2026 → Sep 2029 expected | acute graft versus host disease | Nanfang Hospital, Southern Medical University | Not yet recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gecacitinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07197112 ↗ |
| Known as | gecacitinib (also known as jaktinib) | “gecacitinib (also known as jaktinib)” NCT07285889 ↗ |
| Known as | Gecacitinib Hydrochloride Tablets | “Gecacitinib Hydrochloride Tablets: 100 mg twice daily (BID), orally, on an empty stomach.” NCT07445893 ↗ |
| Known as | Jaktinib | “Gecacitinib (also known as Jaktinib) combined glucocorticoids” NCT07285889 ↗1“Gecacitinib (also known as Jaktinib)” NCT07471503 ↗ |
| Action | Inhibit | “a novel JAK and ACVR1 inhibitor” NCT07012304 ↗ |
| Route | Oral | “Oral” NCT06883526 ↗ |
| Target | ACVR1 | “a novel JAK and ACVR1 inhibitor” NCT07012304 ↗ |